These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 17016520)
1. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Wolf-Yadlin A; Kumar N; Zhang Y; Hautaniemi S; Zaman M; Kim HD; Grantcharova V; Lauffenburger DA; White FM Mol Syst Biol; 2006; 2():54. PubMed ID: 17016520 [TBL] [Abstract][Full Text] [Related]
2. Towards comprehensive characterization of HER2 overexpression. Berezov A; Greene MI Mol Syst Biol; 2006; 2():55. PubMed ID: 17016521 [No Abstract] [Full Text] [Related]
3. Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. Kumar N; Wolf-Yadlin A; White FM; Lauffenburger DA PLoS Comput Biol; 2007 Jan; 3(1):e4. PubMed ID: 17206861 [TBL] [Abstract][Full Text] [Related]
4. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. Ram TG; Hosick HL; Ethier SP J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304 [TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Ram TG; Ethier SP Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665 [TBL] [Abstract][Full Text] [Related]
6. Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Kumar N; Afeyan R; Kim HD; Lauffenburger DA Mol Pharmacol; 2008 Jun; 73(6):1668-78. PubMed ID: 18349105 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
8. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604 [TBL] [Abstract][Full Text] [Related]
9. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783 [TBL] [Abstract][Full Text] [Related]
10. Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro. Patel NV; Acarregui MJ; Snyder JM; Klein JM; Sliwkowski MX; Kern JA Am J Respir Cell Mol Biol; 2000 Apr; 22(4):432-40. PubMed ID: 10745024 [TBL] [Abstract][Full Text] [Related]
11. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Tuck AB; Hota C; Wilson SM; Chambers AF Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946 [TBL] [Abstract][Full Text] [Related]
12. Expression and transactivating functions of the bZIP transcription factor GADD153 in mammary epithelial cells. Talukder AH; Wang RA; Kumar R Oncogene; 2002 Jun; 21(27):4289-300. PubMed ID: 12082616 [TBL] [Abstract][Full Text] [Related]
13. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Sartor CI; Zhou H; Kozlowska E; Guttridge K; Kawata E; Caskey L; Harrelson J; Hynes N; Ethier S; Calvo B; Earp HS Mol Cell Biol; 2001 Jul; 21(13):4265-75. PubMed ID: 11390655 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Motoyama AB; Hynes NE; Lane HA Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928 [TBL] [Abstract][Full Text] [Related]
16. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors. Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419 [TBL] [Abstract][Full Text] [Related]
17. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Badache A; Hynes NE Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191 [TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535 [TBL] [Abstract][Full Text] [Related]
19. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194 [TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]